---
title: "GEMPHARMATECH plans to launch a stock appreciation rights incentive plan in 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/232970586.md"
description: "GEMPHARMATECH announced the draft of its 2025 stock appreciation rights incentive plan, proposing to grant 546,000 stock appreciation rights, accounting for 0.13% of the company's total share capital. The exercise price is set at RMB 7.12 per share, involving 27 incentive recipients, including senior management and key personnel. The incentive plan has a maximum validity period of 36 months, with the exercise divided into two phases, each accounting for 50%"
datetime: "2025-03-24T13:02:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/232970586.md)
  - [en](https://longbridge.com/en/news/232970586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/232970586.md)
---

# GEMPHARMATECH plans to launch a stock appreciation rights incentive plan in 2025

According to the Zhitong Finance APP, GEMPHARMATECH (688046.SH) has disclosed the draft of its stock appreciation rights incentive plan for 2025. The number of stock appreciation rights to be granted to the incentive objects under this incentive plan is 546,000, accounting for approximately 0.13% of the company's total share capital of 41,000,000 shares as of the announcement date of this incentive plan draft. The exercise price of the stock appreciation rights granted under this incentive plan is RMB 7.12 per share.

A total of 27 individuals are involved in the granting of the incentive objects under this incentive plan, including senior management and core personnel who were in office at the time of the announcement of this incentive plan. The validity period of this incentive plan is from the date of grant of the stock appreciation rights until the date when all the stock appreciation rights granted to the incentive objects are exercised or become invalid, with a maximum duration of no more than 36 months. The stock appreciation rights granted under this incentive plan will be exercised in two phases, with the first phase occurring 12 months after the grant date, and the exercise ratio for each phase being 50% and 50%, respectively

### Related Stocks

- [688046.CN](https://longbridge.com/en/quote/688046.CN.md)

## Related News & Research

- [Why Location Is the Only Thing That Matters for Nebius Stock](https://longbridge.com/en/news/286822370.md)
- [Are Wall Street Analysts Predicting McCormick & Company Stock Will Climb or Sink?](https://longbridge.com/en/news/286930030.md)
- [Citi Just Set a Fresh Street-High Target of $287 on Nebius Stock. Here’s Why Analysts Are Bullish.](https://longbridge.com/en/news/286818019.md)
- [If You Invested $100 In Nebius Group Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/286795414.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)